GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC

Honghong Fan; Yuxin Shi; Huiyu Wang; Yuting Li; Jie Mei; Junying Xu; Chaoying Liu

doi:10.2147/IJGM.S408900

GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC

Int J Gen Med. 2023 May 10:16:1757-1769. doi: 10.2147/IJGM.S408900. eCollection 2023.

Authors

Honghong Fan^#¹, Yuxin Shi^#¹, Huiyu Wang¹, Yuting Li¹, Jie Mei¹, Junying Xu¹, Chaoying Liu¹

Affiliation

¹ Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China.

^# Contributed equally.

Abstract

Background: Immunotherapy drugs, immune checkpoint inhibitors (ICIs), have been approved for first- and second-line treatment of non-small cell lung cancer (NSCLC), but only a portion of patients respond to ICIs. It is crucial to screen the beneficiaries of immunotherapy through biomarkers accurately.

Methods: Several datasets were used to explore the predictive value for immunotherapy and immune relevance of guanylate binding protein 5 (GBP5) in NSCLC, including the GSE126044 dataset, The Cancer Genome Atlas (TCGA) dataset, Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset, the Kaplan-Meier plotter dataset, the HLuA150CS02 cohort, and the HLugS120CS01 cohort.

Results: GBP5 was upregulated in tumor tissues but associated with a good prognosis in NSCLC. Moreover, our findings demonstrated that GBP5 was strongly correlated with the expression of many immune-related genes, TIIC levels, and PD-L1 expression based on RNA-seq data onto online databases and validation of the NSCLC tissue microarray using IHC staining. Moreover, pan-cancer analysis has shown that GBP5 was a factor in identifying immuno-hot tumors, except for a few tumor types.

Conclusion: In summary, our current research suggests that GBP5 expression is a potential biomarker for predicting the outcome of NSCLC patients treated with ICIs. More research with large-scale samples is needed to determine their value as biomarkers of ICIs benefit.

Keywords: GBP5; NSCLC; bioinformatics; biomarker; immunotherapy.

Grants and funding

This work was supported by the Wuxi Science and Technology Bureau Foundation (No. N20202018). Beijing Hengji Health Management and Development Foundation (HJ-HX-ZLXD-202209-002).